MAAT Share Price Performance
€4.60
-2.58 (-35.93%)
Price €4.60
Share Price€4.60
MaaT Pharma SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
MAAT Community Narratives
There are no narratives available yet.
Recent MAAT News & Updates
MaaT Pharma SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.93
- Gross Margin
- 52.40%
- Net Profit Margin
- -793.80%
- Debt/Equity Ratio
- 107.1%
MaaT Pharma SA Competitors
Snowflake Analysis
About MAAT
- Founded
- 2014
- Employees
- 65
- CEO
- WebsiteView website
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
French Market Performance
- 7 Days: -0.2%
- 3 Months: 1.9%
- 1 Year: 5.0%
- Year to Date: 6.8%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. More promisingly, the market is up 5.0% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›